Table 1.

Characteristics of Subjects in Vaccine Trial

Subject	Age, y	Sex	Viremiaa	Rashb	Day 28 PRNT60	Day 42 PRNT60	Day 180 PRNT60
1 (Vaccine)	19	F	…	Days 12–20	54	70	30
2 (Vaccine)	26	F	…	…	22	15	<5
3 (Vaccine)	25	M	Days 8–9	…	52	106	22
4 (Vaccine)	20	M	Days 8–9	Days 12–16	26	32	<5
5 (Vaccine)	20	M	Day 6	Days 12–20	33	19	<5
6 (Vaccine)	22	M	…	…	<5	<5	<5
7 (Vaccine)	19	M	…	…	18	8	8
8 (Vaccine)	22	F	Days 5–8	Days 12–20	34	29	8
9 (Vaccine)	19	F	…	…	25	33	<5
10 (Vaccine)	46	F	…	Days 12–16	70	152	64
11 (Placebo)	18	F	…	…	<5	<5	<5
12 (Placebo)	19	M	…	…	<5	<5	<5
13 (Placebo)	45	M	…	…	<5	<5	<5
14 (Placebo)	21	F	…	…	<5	<5	<5

Abbreviations: F, female; M, male; PRNT₆₀, reciprocal serum dilution providing 60% reduction in plaque formation.

^aVirus detected in serum from tissue culture plaque formation assay.

^bFirst and last day on which maculopapular rash was observed..